Mistral Pharma Signs Distribution Agreement for 6 Products
18 Febbraio 2008 - 6:07PM
Marketwired
MONTREAL, QUEBEC ("Mistral") today announced that it has signed
a distribution agreement with an undisclosed pharmaceutical company
for 6 injectable generic products for the Canadian market. Mistral
expects to file these products with Health Canada during 2008.
Mistral estimates that these products target a total market of more
than $ 50 M.
"We are very excited to file these 6 additional products with
Health Canada in 2008" commented Dalal Manoli, Mistral's Vice
President, Sales & Marketing. "This will strengthen our
position as a specialty pharma company with a focus on hospital
products" she added.
About Mistral Pharma Inc.
Mistral Pharma Inc. is an innovative pharmaceutical company that
is active in the reformulation and the commercialization of
already-marketed drugs. Its branded drug delivery products,
MIST-B01, MIST-B02, MIST-B03 & MIST-B04, showed positive
results at their respective first pilot clinical trials. Mistral
also markets INSTILLAGEL� in Canada, a local anesthetic and
antiseptic combination product used for urology procedures. Mistral
has also in-licensed TAMALIS(TM) (Rupatadine) a new antihistamine
and INSTILLAQUILL�, a single use extension tube used in gynecology.
They will both be filed with Health Canada in 2008. Mistral
positions itself as a development and marketing partner with
pharmaceutical companies. More information is available on
Mistral's website at www.mistralpharma.com.
Forward-looking Statements
Except for historical information provided herein, this press
release may contain information and statements of a forward-looking
nature concerning the future performance of Mistral Pharma. These
statements are based on assumptions and uncertainties as well as on
Management's best possible evaluation of future events. Such
factors may include, without excluding other considerations,
fluctuations in quarterly results, evolution in customer demand for
Mistral Pharma's products, the impact of price pressures exerted by
competitors, results from clinical studies and regulatory approval
process as well as general market trends or economic changes. As a
result, readers are advised that actual results may differ from
expected results.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this press release.
Contacts: Mistral Pharma Inc. Bertrand F. Bolduc, B.Pharm., MBA
President & Chief Executive Officer 514-421-1717 ext. 2224
bbolduc@mistralpharma.com Mistral Pharma Inc. Alain Provencher
Vice-president, Finances and Chief Financial Officer 514-421-1717
ext. 2232 aprovencher@mistralpharma.com
Grafico Azioni Mistral Pharma (TSXV:MIP)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Mistral Pharma (TSXV:MIP)
Storico
Da Lug 2023 a Lug 2024
Notizie in Tempo Reale relative a Mistral Pharma (Venture Exchange Canada (TSXV)): 0 articoli recenti
Più Mistral Pharma Inc. Articoli Notizie